Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review (Q38542209)

4 September 2017

1 reference

title

Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review (English)

1 reference

4 September 2017

1 reference

1 reference

1 reference

Harleen K Dyal

1

1 reference

4 September 2017

Maria Aguilar

2

1 reference

4 September 2017

Taft Bhuket

3

1 reference

4 September 2017

Benny Liu

4

1 reference

4 September 2017

Edward W Holt

5

1 reference

4 September 2017

Sharon Torres

6

1 reference

4 September 2017

Ramsey Cheung

7

1 reference

4 September 2017

Robert J Wong

8

1 reference

4 September 2017

3 July 2015

1 reference

Digestive Diseases and Sciences

4 September 2017

1 reference

4 September 2017

60

1 reference

4 September 2017

9

1 reference

4 September 2017

2813-2824

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-015-3760-3

4 September 2017

0 references

cites work

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Contribution of obesity to hepatitis C-related fibrosis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

The impact of hepatic steatosis on the natural history of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Steatosis affects chronic hepatitis C progression in a genotype specific way

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Epidemiology of alcoholic and nonalcoholic fatty liver disease in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Is genotype 3 of the hepatitis C virus the new villain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

Association of type II diabetes mellitus with hepatocellular carcinoma occurrence--a case control study from Kathmandu Valley.

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS10620-015-3760-3

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/26138651

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26138651

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26138651

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10620-015-3760-3

1 reference

Dimensions Publication ID

4 September 2017

0 references

1 reference